Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-24-030159
Filing Date
2024-12-26
Accepted
2024-12-26 16:29:13
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 12890
2 JOINT FILING AGREEMENT ex-99-12262024_061232.htm EX-99.1 3395
  Complete submission text file 0001415889-24-030159.txt   18011
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Subject) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90033 | Film No.: 241581362
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 8 RUE LOU HEMMER SENNINGERBERG N4 L-1748
Business Address 8 RUE LOU HEMMER SENNINGERBERG N4 L-1748 41.443666611
Nextech Crossover I GP S.a r.l. (Filed by) CIK: 0001916761 (see all company filings)

EIN.: 000000000 | State of Incorp.: N4 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A